Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients With Atrial Fibrillation and Diabetes | JACC: Cardiovascular Interventions
RE-DUAL PCI™ vs PIONEER AF-PCI™
PDF) Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in
The effect of sex on the efficacy and safety of dual antithrombotic
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Cardiorrenal.es | ACOD - Evidencia Científica - Fibrilación Auricular - Subanálisis REDUAL PCI LIP 2019
RE-DUAL PCI: Subgroup Analysis on baseline PPI use in post PCI | boehringerone.com
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI - ScienceDirect
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI | JACC: Cardiovascular Interventions
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
RE-DUAL PCI Trial: Inclusion and Main Exclusion Criteria and Study Design | Radcliffe Vascular
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
PCRonline - The RE-DUAL PCI trial subanalysis: In spite of... | Facebook
JCM | Free Full-Text | Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial - ScienceDirect
Updates in Anticoagulation: Key Sessions at ESC 2017
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download
Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. | Semantic Scholar
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Scheme of two options for antithrombotic combination therapy for... | Download Scientific Diagram
AF and PCI in Practice. - ppt download
Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis | tctmd.com
Patient enrolment completed for RE-DUAL PCI™ study assessing dabigatran in atrial fibrillation patients after PCI with stenting | Business Wire
